The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...

This review summarizes the mechanisms of action and clinical activity of IMiDs in MM. Multiple myeloma (MM) is a malignant plasma cell disorder accounting for approximately 10% of all hematologic ...

1 Multiple myeloma originates in blood plasma cells ... sometimes without warning, and the mechanisms that render the disease incurable are not well understood. Many patients therefore require ...

Antengene’s Xpovio approved for reimbursement in Taiwan to treat adult patients with relapsed/refractory multiple myeloma: Shanghai Friday, February 14, 2025, 16:00 Hrs [IST] An ...

Researchers sought to determine whether teclistamab would lead to a clinical response in patients with relapsed/refractory multiple myeloma.

New research shows that maintaining a healthy weight following a monoclonal gammopathy of undetermined significance diagnosis ...

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response ...

Researchers sought to identify prognostic factors for survival in patients with newly diagnosed multiple myeloma.

In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.

The phase 2 REST trial by Frida Bugge Askeland and colleagues, reported in The Lancet Haematology, provides insight into ...